Illumina, Inc. (ILMN) Position Trimmed by Alpha Quant Advisors LLC
Alpha Quant Advisors LLC trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 28.1% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 794 shares of the life sciences company’s stock after selling 310 shares during the period. Alpha Quant Advisors LLC’s holdings in Illumina were worth $246,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Massmutual Trust Co. FSB ADV increased its position in Illumina by 83.0% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 39 shares during the last quarter. First Manhattan Co. increased its position in Illumina by 18.8% in the 1st quarter. First Manhattan Co. now owns 3,464 shares of the life sciences company’s stock worth $1,076,000 after purchasing an additional 547 shares during the last quarter. Sapphire Star Partners LP acquired a new position in Illumina in the 4th quarter worth about $360,000. Machina Capital S.A.S. acquired a new position in Illumina in the 4th quarter worth about $1,099,000. Finally, Ardevora Asset Management LLP increased its position in Illumina by 14.2% in the 1st quarter. Ardevora Asset Management LLP now owns 101,212 shares of the life sciences company’s stock worth $31,446,000 after purchasing an additional 12,600 shares during the last quarter. 90.80% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ ILMN opened at $300.59 on Tuesday. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27. The stock has a market cap of $45.22 billion, a PE ratio of 52.55, a P/E/G ratio of 2.14 and a beta of 1.15. Illumina, Inc. has a 52 week low of $261.61 and a 52 week high of $372.61.
ILMN has been the topic of several research reports. Deutsche Bank lowered Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price on the stock. in a research report on Friday, January 25th. BidaskClub lowered Illumina from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th. Leerink Swann raised Illumina to an “outperform” rating and dropped their target price for the stock from $380.00 to $365.00 in a research report on Wednesday, January 30th. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Finally, Bank of America reaffirmed a “buy” rating and issued a $355.00 target price on shares of Illumina in a research report on Wednesday, January 30th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $353.58.
In other news, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $300.00, for a total transaction of $990,000.00. Following the transaction, the director now owns 341,568 shares of the company’s stock, valued at approximately $102,470,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Mostafa Ronaghi sold 10,000 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $305.49, for a total value of $3,054,900.00. Following the transaction, the senior vice president now directly owns 87,414 shares in the company, valued at approximately $26,704,102.86. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,329 shares of company stock worth $15,648,675. 0.38% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/illumina-inc-ilmn-position-trimmed-by-alpha-quant-advisors-llc/3017255.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: How are institutional investors different from individual investors?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.